A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Clinical trial NCT03745287 · COMPLETED

Trial details

NCT number: NCT03745287
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Sickle Cell Disease Hematological Diseases Hemoglobinopathies

Start date: 2018-11-27
Primary completion: 2025-07-07
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.